Nasdaq · Healthcare

Century Therapeutics, Inc. (IPSC)

As-reported financials and recent SEC filings for Century Therapeutics, Inc., latest fiscal period FY2025. Every figure is pulled straight from the company’s EDGAR filings — no estimates.

Snapshot

Revenue

$109.2M

Net income

$-9.6M

Net margin

-8.8%

Diluted EPS

$-0.14

ROE

-6.0%

P/E (TTM)

—

Market cap

—

Debt / equity

—

Income statement (as reported)

Line	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	$109.2M	$6.6M	$2.2M	$5.2M	—
Gross profit	—	—	—	—	—
Operating income	$-17.3M	$-138.1M	$-146.5M	$-133.8M	$-94.9M
Net income	$-9.6M	$-126.6M	$-136.7M	$-130.9M	$-95.8M
Diluted EPS	$-0.14	$-1.61	$-2.30	$-2.96	$-2.96

Source: company XBRL financial statements on SEC EDGAR.

Recent SEC filings

8-K2026-06-16

42026-06-15

42026-06-15

42026-06-15

42026-06-15

42026-06-12

42026-06-12

1442026-06-12

Largest Healthcare peers

UNH

UNITEDHEALTH GROUP INC

All Healthcare companies →

Go deeper on IPSC

Search Century Therapeutics, Inc.’s filings with cited answers, compare it against peers, build an operating model, and track it in your portfolio — all in one place.

Start free

Or check your whole portfolio free — no account needed.

Data sourced from SEC EDGAR (public domain). Figures are as-reported and may be unaudited or restated; verify against the source filing before relying on them. Informational only — not investment advice.